Bayesian methods for the design and analysis of noninferiority trials

被引:17
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [21] Assessing overall evidence from noninferiority trials with shared historical data
    Soon, Guoxing
    Zhang, Zhiwei
    Tsong, Yi
    Nie, Lei
    STATISTICS IN MEDICINE, 2013, 32 (14) : 2349 - 2363
  • [22] Bayesian survival analysis in clinical trials: What methods are used in practice?
    Brard, Caroline
    Le Teuff, Gwenael
    Le Deley, Marie-Cecile
    Hampson, Lisa V.
    CLINICAL TRIALS, 2017, 14 (01) : 78 - 87
  • [23] Statistical Methods in Recent HIV Noninferiority Trials: Reanalysis of 11 Trials
    Flandre, Philippe
    PLOS ONE, 2011, 6 (09):
  • [24] Assessment of Noninferiority (and Equivalence) for Simple Crossover Trials Using Bayesian Approach
    Yang M.
    Statistics in Biosciences, 2018, 10 (3) : 506 - 519
  • [25] Noninferiority trials
    Steven M Snapinn
    Trials, 1 (1)
  • [26] Design of HIV noninferiority trials: where are we going?
    Flandre, Philippe
    AIDS, 2013, 27 (04) : 653 - 657
  • [27] Bayesian Design of Proof-of-Concept Trials
    Fisch, Roland
    Jones, Ieuan
    Jones, Julie
    Kerman, Jouni
    Rosenkranz, Gerd Karl
    Schmidli, Heinz
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (01) : 155 - 162
  • [28] Bayesian Design of Proof-of-Concept Trials
    Roland Fisch
    Ieuan Jones
    Julie Jones
    Jouni Kerman
    Gerd Karl Rosenkranz
    Heinz Schmidli
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 155 - 162
  • [29] Key insights and challeneges in noninferiority trials
    Hong, Boohwi
    Lee, Dong-Kyu
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2024, 77 (04) : 423 - 431
  • [30] Assessing additional benefit in noninferiority trials
    Kieser, Meinhard
    Stucke, Kathrin
    BIOMETRICAL JOURNAL, 2016, 58 (01) : 154 - 169